Key result
Ticagrelor monotherapy cuts major bleeding ~63% vs. continued DAPT after 3-month PCI.
Why the study?
Discontinuation of aspirin after a short course of dual antiplatelet therapy has emerged as a bleeding reduction strategy, but its safety and efficacy in patients with ACS undergoing PCI required further evaluation.
Does ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduce major bleeding without increasing ischemic risk compared to continued ticagrelor plus aspirin in patients with ACS undergoing PCI?
Meta-Analysis (n=7,529)
Individual patient data pooled from 2 randomized controlled trials (TWILIGHT and TICO)
Yes
Does ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduce major bleeding without increasing ischemic risk compared to continued ticagrelor plus aspirin in patients with ACS undergoing PCI?
In patients with ACS undergoing PCI, dropping aspirin after 3 months of DAPT and continuing ticagrelor monotherapy reduces major bleeding without increasing ischemic events.
Answers are grounded in this paper and cite their sources.
Supports ticagrelor monotherapy after 3 months DAPT in ACS-PCI to reduce major bleeding; extends evidence for early aspirin discontinuation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Baber et al. (2023) conducted a meta-analysis in Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (n=7,529). Ticagrelor monotherapy (after 3 months of DAPT) vs. Continued ticagrelor plus aspirin (DAPT) was evaluated on Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding occurring between 3 and 12 months after index PCI (HR 0.37, 95% CI 0.24-0.56, p=<0.001 for superiority). Ticagrelor monotherapy after 3 months of DAPT reduced BARC 3 or 5 bleeding compared with ticagrelor plus aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: